在CNS试验中解决评级人员功能失明的方法
Steven D Targum1, William P Horan2,3, Vicki G Davis4
1, Boston, MA, USA. sdtargum@yahoo.com.
Translational psychiatry
|February 7, 2025
概括
在临床试验中,对精神分裂症患者的诺米林/ (KarXT) 进行了功能性失明的评估. 治疗出现的不良事件 (TEAE) 并没有影响试验结果,证实了药物.
科学领域:
- 临床试验方法论 临床试验方法论
- 心理药理学 心理药理学
- 神经科学是一个神经科学.
背景情况:
- 治疗出现的不良事件 (TEAE) 可以通过功能地揭开参与者和临床医生的盲目性来危及临床试验的完整性.
- 由于主观的症状评估,中枢神经系统研究特别脆弱.
- 赞诺梅林/托斯皮 (KarXT) 是一种M1/M4肌肉蛋白受体激动剂,可能会引起胆固醇副作用.
研究的目的:
- 在临床试验中评估潜在的功能失明,用于治疗精神分裂症的xanomeline/trospium.
- 为了确定胆固醇TEAE是否会影响观测到的xanomeline/trospium疗效.
- 评估远程评分员评估和子组分析在检测失明时的有用性.
主要方法:
- 来自三项双盲,安慰剂对照试验的汇总数据,在急性精神病中使用xanomeline/trospium.
- 盲目的远程评级者得分与基于现场的阳性和阴性综合征量表 (PANSS) 访谈的比较.
- 基于胆固醇TEAE存在或不存在的参与者子组的特点分析.
主要成果:
- 远程和现场的PANSS分数显示出高相关性,表明可靠的评估.
- 与安慰剂相比,xanomeline/trospium在PANSS得分上显示出显著的改善.
- 治疗响应显着更大,使用xanomeline/trospium,不管TEAEs.
结论:
- 由于TEAE导致的功能失明并没有影响xanomeline/trospium试验的疗效研究结果.
- 远程评估者评估和子组分析是评估试验完整性的有价值方法.
- 在精神分裂症中,xanomeline/trospium的疗效很强大,并没有受到不良事件的干扰.
相关概念视频
02:07Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
01:11Blinding
2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K